Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Aim(s): We sought to determine the most sensitive and specific biomarker for screening for CHD.
Materials and methods: Patients underwent echocardiography and blood sampling for analysis of Chromogranin A and B, N-terminal-pro-BNP (NT-proBNP) and plasma 5-Hydroxyindoleacetic acid (5HIAA). CHD was defined as thickened, regurgitant right-sided valve, and quantified using a validated scoring system (Bhattacharyya, 2008).
To read the full abstract, please log into your ENETS Member account.